O-2050
Δ8-THC sulfonamide analogue proposed as a neutral CB1 antagonist (Ki 2.5 nM); partial agonist on cAMP and in THC discrimination, antagonist in the vas deferens.
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
C₂₃H₃₁NO₄S
CID 16102146
- Family
- Synthetic CB receptor agonistResearch ligand or medicine
- Molar mass
- 417.60 g/mol
Updated on
In plain terms
O-2050 was meant to be a laboratory tool able to block the CB1 receptor without doing anything else. A 2011 study showed that the picture is more mixed: a blocker in some tests on cells and tissues, it behaves like a partial cannabinoid in other tests and in mice. No study in humans was found.
Receptors and activity
Target network
- Activates
- Binds or modulates
The lower the cited value, the closer the target sits to O-2050: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of O-2050.
CB1CB1 found in 7 regions of the body
- Basal gangliadenseMost dense in basal ganglia outflow nuclei1
- CerebellumdenseVery dense in the cerebellum1
- HippocampusdenseVery high concentrations in the hippocampus2
- AmygdaladenseHigh concentrations in the amygdala2
- CortexpresentPresent throughout the neocortex2
- Adipose tissuepresentExpressed in adipose tissue3
- GutpresentColonic epithelium, smooth muscle and plexus4
Map sources
- Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
- Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)
Cited values
- CB1Partial agonistKi = 2.5 nM · rat77 out of 100
Wiley et al., Eur J Pharmacol 2011 (full text PMC3034309, table 1) (new tab) · [3H]CP55,940 displacement, rat cerebellum (2.5 ± 0.4 nM); cAMP (human CB1, CHO cells): partial agonist, Emax 37.4% against 74.4% for CP55,940 (EC50 40.4 nM); GTPγS: maximal stimulation of 11 ± 3%, KB 22 ± 8 nM; mouse vas deferens: pure antagonist, KB 1.0 ± 0.1 nM
- CB2Binding (function not established)Ki = 0.2 nM · mouse95 out of 100
Wiley et al., Eur J Pharmacol 2011 (full text PMC3034309, table 1) (new tab) · mouse CB2 expressed in CHO cells (0.2 ± 0.1 nM); functional efficacy at CB2 not characterised in the study
Pharmacology
O-2050 illustrates the difficulty of obtaining a truly neutral CB1 antagonist, rimonabant behaving as an inverse agonist at high concentrations. A sulfonamide analogue of Δ8-THC, it was widely used as a putative neutral antagonist, until the systematic evaluation by Wiley and colleagues (2011). Its binding is good (Ki 2.5 nM at rat CB1 and 0.2 nM at mouse CB2). In vitro, it antagonises agonists in the mouse vas deferens and on GTPγS binding, with no notable activity of its own; but on cAMP it acts as a partial agonist (Emax 37.4% versus 74.4% for CP55,940). In vivo in mice, it blocked neither Δ9-THC nor WIN 55,212-2, even given into the cerebral ventricles, it stimulated locomotor activity, decreased food intake and fully substituted for Δ9-THC in discrimination. The authors conclude that it cannot be classified as a neutral antagonist. These results are preclinical; no study in humans was found.
Key sources.
- Wiley JL et al. Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB1 receptor antagonist. Eur J Pharmacol, 2011 (new tab)PMID 21114999
- Meye FJ et al. Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity. Mol Psychiatry, 2013 (new tab)PMID 23070073
- PubChem, O-2050, CID 16102146 (identifiers and properties) (new tab)
History
- Source
- An entirely synthetic compound with no natural occurrence. It is known as a pharmacology reagent (supplied by Organix in the study by Wiley et al. 2011); no clinical development was found in the sources consulted.
Origin
Laboratory synthesis
No biological pathway: O-2050 is a synthetic compound, a sulfonamide derivative of Δ8-THC, unrelated to the plant cannabinoid pathway.
Legal framework
- European Union
The substance is not listed in the Annex to Council Framework Decision 2004/757/JHA (consolidated version of 12 January 2026), which lists the new psychoactive substances controlled at European Union level; control is a matter for national law. It is not listed in the schedules of the 1971 Convention on Psychotropic Substances (INCB Green List, 36th edition, 2025, text reviewed). No marketing authorisation was found.
- France
O-2050 is not named in the ANSM consolidated list of narcotics (updated 16/02/2026). On a literal reading of the generic clause "any substance derived from the benzo[c]chromene nucleus" (annex IV, decisions of 22 May and 3 June 2024), it has a nucleus partly hydrogenated on ring A, a hydroxyl at position 1, two methyls at position 6, a methyl at position 9 and, at position 3, an alkynyl chain (hex-4-ynyl), motifs the text lists; but this chain carries a terminal methanesulfonamide group, whereas the text admits as chain substituents only alkyls, cyclic or not, heterocyclic or not. Inclusion of O-2050 in the clause is therefore not established by the text and remains to be confirmed with the ANSM. The stated exclusions (CBN, CBNA, THCV, THCVA, THCA) do not concern it. No marketing authorisation was found.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
Synthetic CB receptor agonist › Research ligand or medicine
- Class
classical
- Verification
Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.
- Wikipedia (English)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Wiley JL et al. Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB1 receptor antagonist. Eur J Pharmacol, 2011 (new tab)PMID 21114999
- Meye FJ et al. Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity. Mol Psychiatry, 2013 (new tab)PMID 23070073
- PubChem, O-2050, CID 16102146 (identifiers and properties) (new tab)
Identifiers
Names
- IUPAC name
- N-[6-[(6aR,10aR)-1-hydroxy-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-3-yl]hex-4-ynyl]methanesulfonamide
- Other names
- O 2050 · O2050
Identifiers
- Formula
- C₂₃H₃₁NO₄S
- PubChem CID
- 16102146(new tab)
- ChEBI
- 92047(new tab)
- InChIKey
- DJTGGIYZQHHLGJ-RTBURBONSA-N
- SMILES
- CC1=
CC[C@@H] 2[C@@H] (C1) C3= C(C= C(C= C3O) CC#CCCCNS(= O) (= O) C) OC2(C) C
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.